Arimidex/Tamoxifen neo adjuvant study in premenopausal patients with breast cancer under anti hormonal treatment

Study identifier:D539BC00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Multi-centre, randomised, double-blind, parallel-group study to compare efficacy and safety between anastrozole (ZD1033) and tamoxifen in pre- and post-operative administration under goserelin acetate treatment for premenopausal breast cancer patients

Medical condition

Breast Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Tamoxifen, Anastrazole (Arimidex), Goserelin acetate (Zoladex)

Sex

Female

Actual Enrollment

197

Study type

Interventional

Age

20 Years +

Date

Study Start Date: 01 Oct 2007
Primary Completion Date: 01 Nov 2009
Study Completion Date: 01 Dec 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria